057sek
-2,0 %
Date:2025-10-14Time:14:52:56Latest report:Q1-2026List:First NorthTicker:BIOVIC B
Market Cap:56 msekEnterprise Value:54 msekNet Sales:9,50 msekEarnings:-82,5 msekEmployees:0ISIN:SE0008613731

Ratios

10-year key figure history for Biovica turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Biovica with index and moving average MA50 and MA200.

Stockprice:0,57
MA50:0,63
MA200:1,05
Price/MA200:-45,2 %
RSI (14):32,5
Price/MA50:-8,6 %

Description

Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.

Biotechnology